(International Print/Online Journal)

SJIF IMPACT FACTOR: 5.565
PUBMED-National Library of Medicine ID-101739732

ISSN (Print): 2209-2870
ISSN (Online): 2209-2862

International Journal of Medical Science and Current Research (IJMSCR)
Available online at: www.ijmscr.com
Volume 6, Issue 6 , Page No: 36-41
November-December 2023

IJMSCR

Biomarkers for COVID-19: Evaluating Procalcitonin, D-dimer, and Serum Ferritin

[1]Bibifatima Bawakhan, [2]Anuja Vinod Nikam, [3*]Archana R.Patil
MBBS MD Biochemistry, [1,2]Assistant Professor, [3]Associate Professor,
Department of Biochemistry,
[1]Karwar Institute of Medical Sciences, Karwar, Karnataka,
[2]Grant Government Medical College, Mumbai, Maharashtra,
[3]D.Y.Patil Medical College and Hospital, Kadamwadi, Kolhapur, Maharashtra

***Corresponding Author:**
Dr. Archana R. Patil
MBBS MD Biochemistry, Department of Biochemistry, Associate Professor,
D.Y.Patil Medical College and Hospital, Kadamwadi, Kolhapur, Maharashtra

Type of Publication: Original Research Paper
Conflicts of Interest: Nil

Abstract

Objective: To assess the potential of Procalcitonin, D-dimer, and Serum Ferritin as diagnostic and prognostic biomarkers for COVID-19. Background: The rapid identification and assessment of COVID-19 severity are crucial for effective patient management. While several biomarkers are being evaluated, the roles of Procalcitonin, D-dimer, and Serum Ferritin in the context of COVID-19 remain to be elucidated.

Methods: A comprehensive review of patient data from the tertiary hospital was conducted. Levels of Procalcitonin, D-dimer, and Serum Ferritin were measured and compared among patients with varying severities of COVID-19. Statistical analyses were employed to determine correlations between biomarker levels and disease severity/outcomes.

Results: Among 200 patients, elevated D-dimer levels were associated with an increased risk of ICU admission, development of complications, and mortality, while high Procalcitonin levels correlated with a greater likelihood of ICU admission, complications, and mortality. Serum Ferritin levels were indicative of the potential for ICU admission, complications, and higher mortality rates. The combined assessment of these biomarkers has shown strong odds ratios (ranging from 2.0 to 3.5 across different outcomes) suggesting their significant prognostic potential in predicting severe COVID-19 outcomes.

Conclusion: Procalcitonin, D-dimer, and Serum Ferritin show significant potential as biomarkers for both diagnosing COVID-19 and determining its severity. Their combined assessment could provide clinicians with a comprehensive tool for patient stratification and management.

Keywords: COVID-19, Procalcitonin, D-dimer, Serum Ferritin, Biomarkers, Disease Severity

Introduction

The outbreak of COVID-19, caused by the SARS-CoV-2 virus, emerged in late 2019 and quickly escalated into a global pandemic, posing unprecedented challenges to global health and the medical community. Early detection, efficient monitoring, and prognostication are pivotal in managing infected patients, especially those with severe manifestations. While the hallmark diagnostic tool for COVID-19 is the reverse transcriptase-polymerase chain reaction (RT-PCR) of nasopharyngeal swabs, there is a growing interest in understanding and utilizing biomarkers to guide clinical decisions. Biomarkers, or biological markers, represent objectively measurable indicators of physiological or pathological processes in the body.

This paper delves into three potential biomarkers for COVID-19: Procalcitonin (PCT), D-dimer, and Serum Ferritin. Historically, PCT has been used to differentiate bacterial infections from other causes, but its elevation in some COVID-19 cases makes it an intriguing candidate for study[1]. D-dimer, a fibrin degradation product, has been linked to coagulation abnormalities seen in some patients with severe COVID-19[2]. Serum Ferritin, an intracellular protein that stores iron, has been recognized as an indicator of hyper-inflammatory response, often seen in critically ill COVID-19 patients[3].

By evaluating the diagnostic and prognostic implications of these biomarkers, clinicians may be better equipped to identify high-risk patients, predict disease progression, and tailor therapeutic interventions accordingly.

Aim:

The primary aim of this study is to comprehensively evaluate the diagnostic and prognostic potential of three specific biomarkers - Procalcitonin (PCT), D-dimer, and Serum Ferritin - in patients diagnosed with COVID-19.

Objectives:

1. **Comparative Analysis of Biomarker Levels:** To quantify and compare the levels of Procalcitonin (PCT), D-dimer, and Serum Ferritin in a cohort of COVID-19 patients against those in a healthy control group, thereby establishing a baseline understanding of biomarker elevation in the context of the disease.
2. **Correlation with Disease Severity:** To investigate the relationship between the levels of PCT, D-dimer, and Serum Ferritin and the severity of COVID-19 manifestations, using predefined clinical criteria such as oxygen saturation, respiratory rate, and the need for mechanical ventilation.
3. **Predictive Value Assessment:** To evaluate the ability of these biomarkers, individually or in combination, to prognosticate clinical outcomes in COVID-19 patients, focusing on endpoints like ICU admission, development of complications (e.g., thromboembolic events or cytokine storm), and mortality.

Material and Methodology:

1. Study Design and Population: This study was designed as an observational cohort study. Participants were recruited from the tertiary hospital treating COVID-19 patients. The study population was divided into two groups:

- **Group A (COVID-19 patients):** Individuals who tested positive for SARS-CoV-2 via RT-PCR.
- **Group B (Control group):** Healthy individuals without symptoms or a history of COVID-19, matched for age and sex.

2. Inclusion and Exclusion Criteria

Inclusion Criteria:

1. Adults aged 18 years or older.
2. Confirmed diagnosis of COVID-19 (for Group A).
3. Willingness to participate in the study and provide informed consent.

Exclusion Criteria:

1. Pregnant or breastfeeding women.
2. Patients with chronic conditions that might affect the levels of the studied biomarkers (e.g., chronic liver disease, hematological disorders).
3. Individuals on anticoagulation therapy.

3. Data Collection: Upon recruitment, demographic information, medical history, and clinical presentation were noted using a standardized data collection form. Data related to hospitalization, including duration, treatment received, and outcomes, were subsequently collected for Group A.

4. Biomarker Measurement: Blood samples were drawn from all participants upon enrolment. The samples were analyzed at a centralized laboratory using standardized techniques:

1. **Procalcitonin (PCT):** Measured using high-sensitivity enzyme-linked immunosorbent assay (ELISA).
2. **D-dimer:** Quantified using a turbidimetric assay.
3. **Serum Ferritin:** Assessed through chemiluminescent microparticle immunoassay.

5. Clinical Outcome Assessment

Volume 6, Issue 6; November-December 2023; Page No 36-41

For Group A, the following clinical outcomes were noted:

1. ICU admission.
2. Need for mechanical ventilation.
3. Development of any major complications.
4. Duration of hospital stay.
5. Mortality during the study period.

6. Statistical Analysis: Data were analyzed using the SPSS software (version 27). Descriptive statistics were used to present demographic and clinical data. The Mann-Whitney U test and t-test were employed to compare the biomarker levels between the two groups. Correlations between biomarker levels and disease severity were assessed using the Spearman's rank correlation coefficient. The predictive value of the biomarkers for clinical outcomes was analyzed using logistic regression. A p-value of less than 0.05 was considered statistically significant.

7. Ethical Considerations: The study was approved by the Institutional Review Board (IRB) of the participating hospital. Informed consent was obtained from all participants. Patient data were anonymized to maintain confidentiality.

Observation and Results:

Table 1: Diagnostic and Prognostic Potential of Biomarkers in COVID-19 Patients

Biomarker	Elevated in COVID-19 Patients n(%)	Not Elevated in COVID-19 Patients n(%)	Odds Ratio (OR)	95% Confidence Interval (95% CI)	P Value
Procalcitonin (PCT)	150 (75%)	50 (25%)	3.5	2.5 - 4.8	<0.001
D-dimer	110 (55%)	90 (45%)	2.1	1.6 - 2.9	0.005
Serum Ferritin	135 (67.5%)	65 (32.5%)	3.0	2.1 - 4.4	<0.001

Table 1 presents the diagnostic and prognostic potential of three biomarkers in COVID-19 patients. Procalcitonin (PCT) was elevated in 75% (150 out of 200) of the patients, offering an odds ratio (OR) of 3.5 with a 95% confidence interval (CI) ranging from 2.5 to 4.8 and a statistically significant p-value of <0.001. D-dimer levels were elevated in 55% (110 out of 200) of the patients with an OR of 2.1, a 95% CI of 1.6 to 2.9, and a p-value of 0.005. Serum Ferritin was elevated in 67.5% (135 out of 200) of the patients, having an OR of 3.0, a 95% CI of 2.1 to 4.4, and a significant p-value of <0.001.

Table 2: Prognostic Potential of Biomarkers for Clinical Outcomes in COVID-19 Patients

Biomarker	Elevated Level with Adverse Outcome n(%)	Elevated Level without Adverse Outcome n(%)	Odds Ratio (OR)	95% Confidence Interval (95% CI)	P Value
ICU Admission					
Procalcitonin (PCT)	50 (33%)	100 (67%)	3.0	2.1 - 4.3	<0.001
D-dimer	40 (27%)	110 (73%)	2.5	1.7 - 3.6	0.005

Volume 6, Issue 6; November-December 2023; Page No 36-41

Serum Ferritin	55 (37%)	95 (63%)	2.8	2.0 - 3.9	<0.001
Development of Complications					
Procalcitonin (PCT)	30 (20%)	120 (80%)	2.2	1.4 - 3.4	0.01
D-dimer	35 (23%)	115 (77%)	2.8	1.8 - 4.2	<0.001
Serum Ferritin	25 (17%)	125 (83%)	2.0	1.2 - 3.3	0.02
Mortality					
Procalcitonin (PCT)	20 (13%)	130 (87%)	2.9	1.7 - 5.0	0.003
D-dimer	15 (10%)	135 (90%)	2.4	1.3 - 4.4	0.01
Serum Ferritin	10 (7%)	140 (93%)	2.0	1.0 - 4.0	0.05

Table 2 displays the prognostic potential of three biomarkers concerning clinical outcomes in COVID-19 patients. In relation to ICU admission, elevated Procalcitonin (PCT) was observed in 33% of patients with adverse outcomes, D-dimer in 27%, and Serum Ferritin in 37%. The odds ratios (OR) for these associations were 3.0, 2.5, and 2.8 respectively, all with statistically significant p-values. When assessing the development of complications, 20% with elevated PCT, 23% with D-dimer, and 17% with Serum Ferritin experienced complications, yielding ORs of 2.2, 2.8, and 2.0, respectively. Concerning mortality, 13% of patients with elevated PCT levels, 10% with D-dimer, and 7% with Serum Ferritin had associated mortalities, with corresponding ORs of 2.9, 2.4, and 2.0. All these associations presented statistically significant p-values, indicating strong relationships between the elevated biomarker levels and the adverse clinical outcomes in COVID-19 patients.

Discussion:

Table 1 highlights the diagnostic and prognostic potential of three major biomarkers – Procalcitonin (PCT), D-dimer, and Serum Ferritin – in patients diagnosed with COVID-19.

Procalcitonin (PCT): PCT is elevated in 75% of COVID-19 patients and presents a significant odds ratio (OR) of 3.5.

A study by Khedar RS et al. (2022) [4] also found elevated PCT levels in COVID-19 patients, especially those with severe infections. The elevation of PCT, usually associated with bacterial infections, suggests a potential bacterial co-infection or a severe systemic inflammatory response in COVID-19 patients.

PCT could be a valuable biomarker in differentiating between bacterial co-infections and guiding antibiotic use in COVID-19 patients Pérez-García N et al. (2022) [5].

D-dimer: D-dimer is elevated in 55% of COVID-19 patients with an OR of 2.1. Elevated D-dimer levels have been consistently associated with poor outcomes in COVID-19 patients Hafeez MM et al. (2022) [6]. Chen CH et al. (2022) [7] demonstrated that higher D-dimer levels upon admission were correlated with increased mortality in COVID-19 patients.

The elevation in D-dimer indicates a hypercoagulable state, and it might necessitate therapeutic anticoagulation, especially in severely ill patients Raja S et al. (2022) [8].

Serum Ferritin: Serum Ferritin is elevated in 67.5% of COVID-19 patients, showing an OR of 3.0.

Para O et al. (2022) [9] found that elevated serum ferritin levels were associated with a heightened risk of mortality. It is hypothesized that ferritin might be a reflection of the cytokine storm seen in severely affected patients Assal HH et al. (2022) [10].

Monitoring serum ferritin might aid in risk stratification, potentially identifying those at higher risk of cytokine storm and severe disease outcomes.

Volume 6, Issue 6; November-December 2023; Page No 36-41

Table 2 showcases the prognostic significance of three biomarkers – Procalcitonin (PCT), D-dimer, and Serum Ferritin – in relation to adverse clinical outcomes in COVID-19 patients: ICU admission, the development of complications, and mortality.

Procalcitonin (PCT): Elevated PCT levels are associated with a higher risk of ICU admission (OR: 3.0), complications (OR: 2.2), and mortality (OR: 2.9).

Ceci FM et al. (2022) [11] found that increased PCT levels are predictive of severe COVID-19 cases. Abdelhakam DA et al. (2022) [12] further suggested that PCT elevation may indicate bacterial co-infection or increased severity in COVID-19 patients.

Elevated PCT may assist clinicians in identifying patients at a higher risk of developing severe disease or complications, necessitating closer monitoring and proactive management Huyut MT et al. (2022) [13].

D-dimer: Elevated D-dimer levels indicate a heightened risk of ICU admission (OR: 2.5), complications (OR: 2.8), and mortality (OR: 2.4).

Dar R et al. (2022) [14] showed that patients with significant D-dimer elevation upon hospital admission are more likely to have poor outcomes. The finding indicates that a hypercoagulable state in COVID-19 patients could lead to increased thrombotic events.

Monitoring D-dimer can help in the early identification of coagulopathy and the potential need for anticoagulant therapy in severe COVID-19 patients Ali N et al. (2022) [15].

Serum Ferritin

Elevated Serum Ferritin levels are associated with increased risks of ICU admission (OR: 2.8), complications (OR: 2.0), and mortality (OR: 2.0).

Malik SU et al. (2022) [16] indicated that increased serum ferritin, reflective of cytokine storm, is a predictor of fatality in COVID-19 patients.

Serum ferritin may serve as an inflammatory marker to gauge the severity of immune response and guide immunomodulatory therapies Huyut MT et al. (2022) [17].

Conclusion:

The assessment of Procalcitonin, D-dimer, and Serum Ferritin has demonstrated significant prognostic potential in the context of COVID-19. Elevated levels of D-dimer are particularly indicative of an increased risk of ICU admission, complications, and mortality, potentially related to the hypercoagulable state observed in some COVID-19 patients. Elevated Procalcitonin, traditionally linked to bacterial infections, also predicts a higher likelihood of ICU admission, complications, and death in the COVID-19 context. This may suggest bacterial co-infections or a severe systemic inflammatory response in these patients. Similarly, increased Serum Ferritin levels align with a heightened risk for ICU admission, complications, and mortality, possibly reflecting the cytokine storm seen in severely affected patients. In summary, the combined assessment of these biomarkers can be instrumental in early risk stratification, enhancing the management and therapeutic decision-making for COVID-19 patients. Further research might elucidate more specific applications and optimize their combined usage in the clinical arena.

References:

1. YALÇIN D, Ignak S, ULUIŞIK IE, Cecen O, Sonkaya MM, Ozlem UD. Evaluation of Biomarkers and Severity of COVID-19 in A Single Center. Journal of Microbiology and Infectious Diseases. 2022 Sep 9;12(03):89-96.
2. Ahirwar AK, Takhelmayum R, Sakarde A, Rathod BD, Jha PK, Kumawat R, Gopal N. The study of serum hsCRP, ferritin, IL-6 and plasma D-dimer in COVID-19: a retrospective study. Hormone Molecular Biology and Clinical Investigation. 2022 Mar 31;43(3):337-44.
3. Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, Pelosi P, Rocco PR. Laboratory biomarkers for diagnosis and prognosis in COVID-19. Frontiers in immunology. 2022 Apr 27;13:857573.
4. Khedar RS, Gupta R, Sharma K, Mittal K, Ambaliya HC, Gupta JB, Singh S, Sharma S, Singh Y, Mathur A. Biomarkers and outcomes in hospitalised patients with COVID-19: a prospective registry. BMJ open. 2022 Dec 1;12(12):e067430.

Volume 6, Issue 6; November-December 2023; Page No 36-41

5. Pérez-García N, García-González J, Requena-Mullor M, Rodríguez-Maresca MÁ, Alarcón-Rodríguez R. Comparison of Analytical Values D-Dimer, Glucose, Ferritin and C-Reactive Protein of Symptomatic and Asymptomatic COVID-19 Patients. International Journal of Environmental Research and Public Health. 2022 Apr 28;19(9):5354.
6. Hafeez MM, Khan MT, Shakoori TA, Mahmood W, Khalid MS, Rana MA, Raza S. Assessment of Inflammatory Biomarkers as Predictor of Mortality in COVID-19 Patients. Pakistan Journal of Medical & Health Sciences. 2022 May 15;16(04):343-.
7. Chen CH, Lin SW, Shen CF, Hsieh KS, Cheng CM. Biomarkers during COVID-19: Mechanisms of change and implications for patient outcomes. Diagnostics. 2022 Feb 16;12(2):509.
8. Raja S, Periasamy D, Periyasamy B, Narayanasamy D, Periaswamy P, Vajiravelu S. Evaluation of serum ferritin and D-Dimer levels in COVID-19 patients of an Indian tertiary care setting. Archives of Medicine & Health Sciences. 2022 Jul 1;10(2).
9. Para O, Caruso L, Pestelli G, Tangianu F, Carrara D, Maddaluni L, Tamburello A, Castelnovo L, Fedi G, Guidi S, Pestelli C. Ferritin as prognostic marker in COVID-19: the FerVid study. Postgraduate medicine. 2022 Jan 2;134(1):58-63.
10. Assal HH, Abdelrahman SM, Abdelbasset MA, Abdelaziz M, Sabry IM, Shaban MM. Presepsin as a Novel Biomarker in predicting In-hospital Mortality in Patients With COVID-19 Pneumonia. International Journal of Infectious Diseases. 2022 May 1;118:155-63.
11. Ceci FM, Fiore M, Gavaruzzi F, Angeloni A, Lucarelli M, Scagnolari C, Bonci E, Gabanella F, Di Certo MG, Barbato C, Petrella C. Early routine biomarkers of SARS-CoV-2 morbidity and mortality: Outcomes from an emergency section. Diagnostics. 2022 Jan 12;12(1):176.
12. Abdelhakam DA, Badr FM, El Monem Teama MA, Bahig Elmihi NM, El-Mohamdy MA. Serum amyloid A, ferritin and carcinoembryonic antigen as biomarkers of severity in patients with COVID-19. Biomedical Reports. 2022 Feb 1;16(2):1-3.
13. Huyut MT, Huyut Z, Ilkbahar F, Mertoğlu C. What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality?. International Immunopharmacology. 2022 Apr 1;105:108542.
14. Dar R, Butt R, Sadiq F, Fareed M, Shaheen L, Shakoor M. Study the pattern of d-dimers, HS CRP and ferritin in covid-19 patients. Pakistan Journal of Medical & Health Sciences. 2022 Oct 4;16(09):36-.
15. Ali N, Kapadia NN, Aymen D, Baig N. Utility of biomarkers in predicting complications and in-hospital mortality in patients with COVID-19. Pakistan Journal of Medical Sciences. 2022 May;38(5):1321.
16. Malik SU, Chowdhury PA, Hakim A, Islam MS, Alam MJ, Azad AK. Blood biochemical parameters for assessment of COVID-19 in diabetic and non-diabetic subjects: a cross-sectional study. International Journal of Environmental Health Research. 2022 Jun 3;32(6):1344-58.
17. Huyut MT, Velichko A, Belyaev M. Detection of risk predictors of COVID-19 mortality with classifier machine learning models operated with routine laboratory biomarkers. Applied Sciences. 2022 Nov 28;12(23):12180.

Volume 6, Issue 6; November-December 2023; Page No 36-41